News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eisai Company, Ltd. (ESALY.PK) Submits Application To Expand Indication Of Anti-Alzheimer's Agent Aricept® As Treatment For Dementia With Lewy Bodies In Japan


12/10/2013 11:04:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Tokyo, Oct 31, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito), announced today that it has filed an application for the anti-Alzheimer's agent Aricept(R) (donepezil hydrochloride, "donepezil") in Japan, requesting a new indication expansion to use the agent in the treatment of dementia with Lewy bodies (DLB).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES